NAD+ has become one of the most talked-about compounds in wellness medicine, and the conversation around it has developed a familiar shape: genuine, interesting biochemistry at the center, surrounded by claims that have gotten well ahead of the evidence.
The biochemistry is not in dispute. NAD+ is essential, it declines with age, and restoring it in animal models produces striking effects. What’s less settled is how much of that translates to humans, at what dose, by what route, and for whom. Any clinic telling you the question is closed is not reading the same literature.
Here’s the version that respects both the promise and the uncertainty.
Nicotinamide adenine dinucleotide is a coenzyme present in every living cell. It’s not a vitamin, not a hormone, and not a drug — it’s a molecule the body manufactures and uses continuously as part of core metabolism.
Its primary role is in energy production. NAD+ functions as an electron carrier, shuttling electrons through the reactions that convert food into ATP, the molecule cells use as fuel. This happens in the mitochondria, and it happens constantly. Without adequate NAD+, cellular energy production is constrained regardless of how much food is available. This is not a supplement-industry claim; it’s foundational biochemistry.
NAD+ also serves as a required substrate for two families of enzymes that have drawn enormous research interest. Sirtuins are involved in DNA repair, metabolic regulation, and cellular stress response. PARP enzymes are central to DNA damage repair. Both consume NAD+ in the process of doing their work, meaning demand rises when the body is under stress or repairing damage.
That consumption creates the central tension. NAD+ is required for energy production and simultaneously consumed by repair processes. When repair demand is high, less is available for
everything else.
NAD+ levels fall substantially with age across tissues. The decline appears to be driven by both reduced synthesis and increased consumption — the body makes less while enzymes that consume it become more active in response to accumulated damage.
Other factors influence the trajectory. Chronic inflammation increases consumption. Metabolic dysfunction, poor sleep, alcohol, and sustained physical or psychological stress all appear to draw on the pool. This is a plausible partial explanation for why the same lifestyle factors that accelerate aging also correlate with the metabolic sluggishness people describe subjectively as running on empty.
The reasoning that follows is straightforward and worth stating plainly: if NAD+ is required for cellular energy and declines with age, restoring levels might restore function. That reasoning is sound. Whether it holds up in practice, in humans, at achievable doses is where honesty is required.
The animal data is genuinely impressive. Restoring NAD+ in aged mice improves mitochondrial function, muscle performance, metabolic markers, and in several studies extends lifespan. These are real findings from serious labs, and they’re the reason the field attracted this much attention.
Human data is considerably thinner. Studies confirm that intravenous NAD+ and its oral precursors raise measurable NAD+ levels in humans, which establishes that the delivery works. Beyond that, the clinical outcome research is early — smaller trials, shorter durations, mixed endpoints, and a good deal still in progress.
NAD+ is not FDA-approved to treat, prevent, or cure any condition, and it should not be described as doing so. What can be said accurately is that the mechanism is well established, that levels demonstrably decline, that restoration is achievable, and that a substantial number of patients report meaningful subjective improvement in energy and mental clarity.
Subjective reports are not the same as controlled trial evidence. They’re also not nothing. The appropriate posture is interest without overclaiming, and that’s the posture worth expecting from any clinic offering it.
NAD+ can be raised two ways: by supplying the molecule directly, or by supplying a precursor the body converts into it.
The precursor route is what oral supplements use, typically nicotinamide riboside or nicotinamide mononucleotide. These are absorbed and converted through the salvage pathway. They reliably raise NAD+ levels and they’re convenient, though conversion is a rate-limited process — the pathway can only move so fast regardless of how much substrate you supply.
Direct NAD+ delivery bypasses the conversion step. This is what intravenous and injectable NAD+ do. The reason the intravenous route dominates is that NAD+ is a large, unstable molecule with poor oral bioavailability — swallowing NAD+ itself is largely a waste, because most of it degrades before it can be used. Delivery directly into circulation avoids that.
Neither route is universally superior. Direct delivery achieves concentrations precursors can’t. Precursors are cheaper, easier, and reasonable for maintenance. Many patients use infusion to establish levels and oral precursors to hold them.
The infusion is the higher-dose approach, run slowly over a long session, and it’s what most protocols use for an initial loading series.
Subcutaneous or intramuscular injection delivers a smaller dose in minutes. It’s substantially more convenient, considerably less expensive, and well suited to maintenance between infusions or to patients who want to trial the compound without committing to a long session.
For patients signaling energy, recovery, or longevity goals, the injection is often the right entry point. It’s a small commitment that answers the question of whether you respond, and responders can escalate to infusion from there.
This section is the one most clinics leave out, and leaving it out is how patients end up alarmed mid-drip.
NAD+ infusion is uncomfortable when run too fast. Patients commonly describe chest tightness, abdominal cramping, flushing, nausea, a sensation of pressure in the head, and a general feeling of intensity. This is a well-documented, expected response to the infusion rate rather than an allergic reaction or a sign that something is wrong.
The management is simple: slow the drip. Symptoms typically resolve within moments of reducing the rate and return if the rate is increased again. This is why NAD+ infusions take as long as they do — a full-dose infusion commonly runs two to four hours, and the duration is dictated by tolerance rather than by volume.
A provider should tell you this before you sit down, stay in communication throughout, and adjust as needed. Anyone who starts a NAD+ drip without explaining the sensation in advance has set you up to be frightened by something predictable.
Most patients tolerate it well once the rate is dialed in. There’s no downtime afterward.
A common approach is a loading series of several infusions over a compressed period, followed by maintenance. The loading phase aims to raise levels meaningfully; maintenance aims to hold them.
Maintenance varies widely. Some patients return for infusion monthly or quarterly. Others transition to injections on a more frequent schedule, or to oral precursors daily, or to some combination. The right cadence depends on how you respond, what you’re managing, and what’s practical.
Effects are not uniform. Some patients notice change during the first infusion. Others notice nothing until several sessions in. Some don’t respond appreciably at all, and that possibility should be acknowledged before you commit to a package rather than discovered after you’ve paid for one.
Patients dealing with age-related decline in energy and recovery capacity are the primary population, and it’s where the mechanistic rationale is strongest.
Athletes and high-output individuals use it for recovery, on the reasoning that training demand increases cellular repair activity and therefore NAD+ consumption.
Patients pursuing longevity-oriented care use it as one component of a broader protocol alongside hormone optimization, metabolic management, and peptide therapy — and that framing is the right one. NAD+ is a component, not a program.
Patients with persistent fatigue should be evaluated before being infused. Fatigue has a long list of identifiable causes, and NAD+ is not the first answer to an unexplained symptom. Bloodwork and a proper workup come first. If thyroid dysfunction or anemia or sleep apnea is driving it, treating that will do more than any infusion.
NAD+ therapy requires medical intake and provider review. Cardiovascular conditions, kidney disease, pregnancy, and certain medication regimens all warrant caution or modification. The infusion itself carries the standard risks of intravenous access — infection, infiltration, vein irritation — which is why sterile technique and clinical oversight are not optional.
Compounding source matters. NAD+ for injection and infusion is a compounded preparation, and where it comes from and under what regulatory framework it was prepared is a fair question to ask any provider. If a clinic can’t answer it, that tells you something.
Every NAD+ service at Optimal Wellness runs under physician supervision with screening beforehand.
We’ll take a full history, discuss what you’re trying to address, and give you a straight answer about whether NAD+ makes sense for your situation — including the honest version of what the evidence does and doesn’t support. If what you’re describing points toward something that needs a workup first, we’ll tell you that instead of selling you a series.
If you want to find out whether you respond before committing to infusions, the injection is a reasonable place to start.
Our clinic is on Central Avenue in St. Petersburg. Consultations are available now.
Book here: Start Your Wellness Journey Today! Book Here – Optimal Wellness
